PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the Association for Professionals in Infection Control Conference June 14-16

DELRAY BEACH, Fla., June 08, 2017 -- PositiveID Corporation (OTCQB:PSIDD), a Life Sciences Company focused on detection and diagnostics, announced today that its Thermomedics subsidiary will exhibit the Caregiver® non-contact thermometer at the 44^th Annual Association for Professionals in Infection Control and Epidemiology (APIC) Conference from June 14-16 at the Oregon Convention Center in Portland, OR.

Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers, which are as much as $0.05 to $0.10 per temperature, storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

PositiveID’s Thermomedics team is exhibiting at the APIC conference to increase exposure and awareness for Caregiver and generate qualified leads for its national network of distributors.

APIC is a nonprofit, professional association comprised of more than 15,000 members whose responsibility is the prevention and control of infections and related adverse outcomes in patients and healthcare workers. APIC promotes wellness and prevents illness and infection worldwide by advancing healthcare epidemiology through education, research, collaboration, practice guidance, and credentialing. APIC’s mission is to create a safer world through the prevention of infection.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics Company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

SAFE HARBOR

Statements about PositiveID's future expectations, including the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market; the Company’s ability to attract and retain new customers; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on May 15, 2017, November 18, 2016, and August 12, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contacts:
PositiveID Corporation
Allison Tomek
(561) 805-8044
[email protected]

Paul Knopick
E & E Communications
940.262.3584
[email protected]